ArticleJournal of experimental & clinical cancer research : CR2026
Endothelial cell-derived IGFBP7 suppresses angiogenesis and tumor progression in colorectal cancer via the VAPA-TGF-β1 pathway.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Subcutaneous transplantation of lung organoids ameliorates vascular dementia via the IGFBP7-Ago2 mediated lung-brain axis.Journal of neuroinflammation · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a leading cause of cancer-related deaths, with the tumor microenvironment (TME) influencing disease progression and therapeutic response. Tumor endothelial cells are crucial in CRC initiation, progression, and metastasis, yet their specific mechanisms are not fully understood.
methodsWe utilized single-cell RNA sequencing, RNAscope, flow cytometry, and immunofluorescence staining to identify and characterize insulin-like growth factor binding-protein 7 (IGFBP7) secretion by tumor endothelial cells, observing a progressive decline in its expression during inflammation-driven tumorigenesis. To elucidate IGFBP7 function, bulk RNA sequencing data were integrated with in vitro and in vivo models. The molecular mechanisms by which IGFBP7 influences the TME were explored through immunoprecipitation mass spectrometry and transmission electron microscopy.
resultsOur findings revealed a progressive decrease in both IGFBP7 expression and secretion by tumor endothelial cells during inflammation-associated colorectal tumorigenesis. Functional analyses confirmed that endothelial-derived IGFBP7 is secreted into the TME, where it exerts anti-angiogenic effects. Moreover, CRC cells have been shown to actively internalize IGFBP7-containing vesicles. IGFBP7 suppresses tumor cell proliferation and migration by inhibiting the expression of EGR1, thereby downregulating the activity of the TGF-β1 signaling pathway. Notably, we identified Vesicle-associated membrane protein-associated protein A (VAPA) as a key mediator in the transport of IGFBP7 vesicles to lysosomes, facilitating IGFBP7 degradation and thereby attenuating its tumor-suppressive function.
conclusionEndothelial cell-derived IGFBP7 suppresses CRC progression via the EGR1/TGF-β1 pathway, while VAPA-mediated lysosomal degradation limits its tumor-suppressive function. These findings highlight endothelial cell-derived IGFBP7 as a promising therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.